RxDoctor Payments Data

George Veliky, OD

Optometrist · Iselin, NJNPI 1932198405

Payments from drug & device makers

$5,035in general payments, 2019–2025

Across 138 payments — averaging $36.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson Surgical Vision, Inc.$863
  • Alcon$547
  • Sight Sciences, Inc.$405
  • Glaukos Corporation$353
  • Biotissue Holdings Inc.$285
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$5,035100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,035 in reported general payments places this provider in the 90th percentile of 1,357 optometrist providers in New Jersey.

See all optometrist providers in New Jersey

Medicare billing

Part B allowed, 2024
$155,994
Medicare patients
446
Services billed
1,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost152$67,104
Timolol Maleate287$21,936
RestasisCyclosporine25$21,028
VyzultaLatanoprostene Bunod28$15,673
Cyclosporine33$12,802
RocklatanNetarsudil Mesylat/Latanoprost15$8,513
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol36$4,666
CombiganBrimonidine Tartrate/Timolol19$4,534
Latanoprost548$4,147
Prednisolone Acetate92$4,111
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat249$3,369
Travoprost19$2,229
Brimonidine Tartrate12$1,283
ValacyclovirValacyclovir Hcl23$1,071
Acetazolamide ErAcetazolamide22$1,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$1,122$92,667196 claims
Bausch & Lomb Americas Inc.Vyzulta$46$15,67328 claims
Aerie Pharmaceuticals, Inc.Rocklatan$105$8,51315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 optometrist providers in New Jersey.

Other optometrist in Iselin

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →